ES3036330T3 - Imidazopyridazines as modulators of il-17 - Google Patents
Imidazopyridazines as modulators of il-17Info
- Publication number
- ES3036330T3 ES3036330T3 ES21729078T ES21729078T ES3036330T3 ES 3036330 T3 ES3036330 T3 ES 3036330T3 ES 21729078 T ES21729078 T ES 21729078T ES 21729078 T ES21729078 T ES 21729078T ES 3036330 T3 ES3036330 T3 ES 3036330T3
- Authority
- ES
- Spain
- Prior art keywords
- substituted
- alkyl
- methyl
- groups
- intermediate product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Lubricants (AREA)
- Fats And Perfumes (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063017682P | 2020-04-30 | 2020-04-30 | |
| PCT/US2021/029641 WO2021222404A1 (en) | 2020-04-30 | 2021-04-28 | Imidazopyridazines as modulators of il-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3036330T3 true ES3036330T3 (en) | 2025-09-17 |
Family
ID=76197556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21729078T Active ES3036330T3 (en) | 2020-04-30 | 2021-04-28 | Imidazopyridazines as modulators of il-17 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11691979B2 (https=) |
| EP (1) | EP4143195B1 (https=) |
| JP (1) | JP7664947B2 (https=) |
| KR (1) | KR20230019507A (https=) |
| CN (1) | CN115884810B (https=) |
| AR (1) | AR121959A1 (https=) |
| AU (1) | AU2021264528A1 (https=) |
| BR (1) | BR112022021962A2 (https=) |
| CA (1) | CA3181676A1 (https=) |
| CO (1) | CO2022017072A2 (https=) |
| EC (1) | ECSP22091485A (https=) |
| ES (1) | ES3036330T3 (https=) |
| IL (1) | IL297705A (https=) |
| JO (1) | JOP20220284A1 (https=) |
| MX (1) | MX2022013647A (https=) |
| PE (1) | PE20230469A1 (https=) |
| TW (1) | TWI874645B (https=) |
| UY (1) | UY39188A (https=) |
| WO (1) | WO2021222404A1 (https=) |
| ZA (1) | ZA202212967B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201909190D0 (en) | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| KR20230019507A (ko) * | 2020-04-30 | 2023-02-08 | 얀센 파마슈티카 엔.브이. | Il-17의 조절제로서의 이미다조피리다진 |
| WO2021220183A1 (en) | 2020-04-30 | 2021-11-04 | Janssen Pharmaceutica Nv | Imidazopyrimidines as modulators of il-17 |
| CA3200594A1 (en) * | 2020-12-14 | 2022-06-23 | UCB Biopharma SRL | Imidazopyridazine derivatives as il-17 modulators |
| WO2023025783A1 (en) | 2021-08-23 | 2023-03-02 | Leo Pharma A/S | Small molecule modulators of il-17 |
| KR20240082371A (ko) | 2021-09-27 | 2024-06-10 | 얀센 파마슈티카 엔브이 | 이미다조피리다진 il-17 억제제 화합물 |
| JP2024536869A (ja) | 2021-09-27 | 2024-10-08 | ヤンセン ファーマシューティカ エヌ．ベー． | イミダゾピリダジンｉｌ－１７阻害剤化合物 |
| WO2023111181A1 (en) | 2021-12-16 | 2023-06-22 | Leo Pharma A/S | Small molecule modulators of il-17 |
| CN118580191A (zh) * | 2022-01-28 | 2024-09-03 | 和记黄埔医药（上海）有限公司 | 用于制备咪唑并[1,2-b]哒嗪类化合物的中间体 |
| WO2023166172A1 (en) | 2022-03-04 | 2023-09-07 | Leo Pharma A/S | Small molecule modulators of il-17 |
| EP4525987A1 (en) * | 2022-05-19 | 2025-03-26 | Dice Alpha, Inc. | Lactam substituted imidazopyridazine il-17a modulators and uses thereof |
| TW202430165A (zh) | 2022-12-02 | 2024-08-01 | 丹麥商理奧藥品公司 | Il-17之小分子調節劑 |
| CN115806503B (zh) * | 2022-12-02 | 2025-03-07 | 中国海洋大学 | 一种选择性组蛋白去乙酰化酶抑制剂及其制备方法和应用 |
| CN121311483A (zh) * | 2023-03-28 | 2026-01-09 | 詹森药业有限公司 | 含内酰胺的咪唑并哒嗪il-17抑制剂化合物 |
| KR20250168657A (ko) * | 2023-04-11 | 2025-12-02 | 다이스 알파, 인크. | 치환된 6-이미다조피리다진 il-17a 조정제 및 그의 용도 |
| WO2025202931A1 (en) | 2024-03-27 | 2025-10-02 | Janssen Pharmaceutica Nv | Imidazopyridazine il-17 inhibitor compounds |
| WO2025247285A1 (zh) * | 2024-05-28 | 2025-12-04 | 西藏海思科制药有限公司 | 一种可抑制il-17a的杂环化合物制备及其用途 |
| WO2026080825A1 (en) * | 2024-10-10 | 2026-04-16 | Revolution Medicines, Inc. | Synthesis of ras inhibitors |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10208349B2 (en) | 2011-01-07 | 2019-02-19 | Ucb Biopharma Sprl | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
| US9284283B2 (en) | 2012-02-02 | 2016-03-15 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating IL-17 |
| ES2666353T3 (es) | 2012-09-06 | 2018-05-04 | Bristol-Myers Squibb Company | Inhibidores de JAK3 de imidazopiridazina y su uso para el tratamiento de enfermedades inflamatorias y autoinmunitarias |
| WO2014066726A2 (en) | 2012-10-26 | 2014-05-01 | Ensemble Therapeutics Corporation | Compounds for modulating il-17 |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| US10035777B2 (en) | 2014-08-05 | 2018-07-31 | Bristol-Myers Squibb Company | Heterocyclic kinase inhibitors |
| US10479793B2 (en) | 2015-11-18 | 2019-11-19 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
| GB201709456D0 (en) | 2017-06-14 | 2017-07-26 | Ucb Biopharma Sprl | Therapeutic agents |
| WO2019138017A1 (en) * | 2018-01-15 | 2019-07-18 | Ucb Biopharma Sprl | Fused imidazole derivatives as il-17 modulators |
| WO2019223718A1 (zh) | 2018-05-22 | 2019-11-28 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| EP3599245A1 (en) | 2018-07-27 | 2020-01-29 | Dompé farmaceutici S.p.A. | Il-17a binding polypeptides and medical uses thereof |
| GB201820166D0 (en) | 2018-12-11 | 2019-01-23 | Ucb Biopharma Sprl | Therapeutic agents |
| GB201820165D0 (en) | 2018-12-11 | 2019-01-23 | Ucb Biopharma Sprl | Therapeutic agents |
| GB201820316D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for IL-17 |
| BR112021010453A2 (pt) | 2018-12-19 | 2021-08-24 | Leo Pharma A/S | Composto, e, composição farmacêutica |
| TWI752400B (zh) | 2019-01-07 | 2022-01-11 | 美商美國禮來大藥廠 | Il-17a抑制劑 |
| TWI839461B (zh) | 2019-02-06 | 2024-04-21 | 美商戴斯阿爾法股份有限公司 | Il-17a調節物及其用途 |
| US20220162191A1 (en) | 2019-03-08 | 2022-05-26 | Leo Pharma A/S | Small molecule modulators of il-17 |
| GB201909190D0 (en) | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| GB201909191D0 (en) | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| GB201909194D0 (en) | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| CN112341441B (zh) | 2019-08-09 | 2022-02-11 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN112341429B (zh) | 2019-08-09 | 2021-11-23 | 成都先导药物开发股份有限公司 | 一种免疫调节剂的中间体化合物 |
| CN112341451B (zh) | 2019-08-09 | 2022-06-17 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2021027722A1 (zh) | 2019-08-09 | 2021-02-18 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN112341442B (zh) | 2019-08-09 | 2021-10-22 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN112341435B (zh) | 2019-08-09 | 2021-10-22 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2021027729A1 (zh) | 2019-08-09 | 2021-02-18 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2021027724A1 (zh) | 2019-08-09 | 2021-02-18 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN112341450B (zh) | 2019-08-09 | 2022-05-17 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2021170627A1 (en) | 2020-02-25 | 2021-09-02 | UCB Biopharma SRL | Difluorocyclohexyl derivatives as il-17 modulators |
| WO2021170631A1 (en) | 2020-02-25 | 2021-09-02 | UCB Biopharma SRL | Difluorocyclohexyl derivatives as il-17 modulators |
| CA3179686A1 (en) | 2020-04-07 | 2021-10-14 | UCB Biopharma SRL | Difluorocyclohexyl derivatives as il-17 modulators |
| WO2021204800A1 (en) | 2020-04-07 | 2021-10-14 | UCB Biopharma SRL | Difluorocyclohexyl derivatives as il-17 modulators |
| MX2022013649A (es) * | 2020-04-30 | 2023-02-01 | Janssen Pharmaceutica Nv | Métodos para identificar moduladores de la ruta de il-17. |
| KR20230019507A (ko) * | 2020-04-30 | 2023-02-08 | 얀센 파마슈티카 엔.브이. | Il-17의 조절제로서의 이미다조피리다진 |
-
2021
- 2021-04-28 KR KR1020227041943A patent/KR20230019507A/ko active Pending
- 2021-04-28 PE PE2022002520A patent/PE20230469A1/es unknown
- 2021-04-28 JP JP2022565972A patent/JP7664947B2/ja active Active
- 2021-04-28 IL IL297705A patent/IL297705A/en unknown
- 2021-04-28 AU AU2021264528A patent/AU2021264528A1/en active Pending
- 2021-04-28 ES ES21729078T patent/ES3036330T3/es active Active
- 2021-04-28 WO PCT/US2021/029641 patent/WO2021222404A1/en not_active Ceased
- 2021-04-28 AR ARP210101149A patent/AR121959A1/es unknown
- 2021-04-28 US US17/242,512 patent/US11691979B2/en active Active
- 2021-04-28 CN CN202180047160.XA patent/CN115884810B/zh active Active
- 2021-04-28 CA CA3181676A patent/CA3181676A1/en active Pending
- 2021-04-28 TW TW110115268A patent/TWI874645B/zh active
- 2021-04-28 EP EP21729078.2A patent/EP4143195B1/en active Active
- 2021-04-28 MX MX2022013647A patent/MX2022013647A/es unknown
- 2021-04-28 UY UY0001039188A patent/UY39188A/es unknown
- 2021-04-28 BR BR112022021962A patent/BR112022021962A2/pt unknown
-
2022
- 2022-01-14 US US17/576,535 patent/US11702422B2/en active Active
- 2022-10-30 JO JOJO/P/2022/0284A patent/JOP20220284A1/ar unknown
- 2022-11-29 CO CONC2022/0017072A patent/CO2022017072A2/es unknown
- 2022-11-29 EC ECSENADI202291485A patent/ECSP22091485A/es unknown
- 2022-11-29 ZA ZA2022/12967A patent/ZA202212967B/en unknown
-
2023
- 2023-04-07 US US18/297,268 patent/US12024524B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PE20230469A1 (es) | 2023-03-14 |
| US20220402922A1 (en) | 2022-12-22 |
| US11702422B2 (en) | 2023-07-18 |
| WO2021222404A1 (en) | 2021-11-04 |
| BR112022021962A2 (pt) | 2023-03-28 |
| JP2023524018A (ja) | 2023-06-08 |
| EP4143195B1 (en) | 2025-05-21 |
| ZA202212967B (en) | 2024-06-26 |
| KR20230019507A (ko) | 2023-02-08 |
| US12024524B2 (en) | 2024-07-02 |
| ECSP22091485A (es) | 2022-12-30 |
| TW202208367A (zh) | 2022-03-01 |
| JOP20220284A1 (ar) | 2022-10-30 |
| CN115884810A (zh) | 2023-03-31 |
| CN115884810B (zh) | 2025-01-17 |
| MX2022013647A (es) | 2023-02-01 |
| UY39188A (es) | 2021-10-29 |
| US11691979B2 (en) | 2023-07-04 |
| IL297705A (en) | 2022-12-01 |
| US20230357254A1 (en) | 2023-11-09 |
| CA3181676A1 (en) | 2021-11-04 |
| AR121959A1 (es) | 2022-07-27 |
| EP4143195A1 (en) | 2023-03-08 |
| EP4143195C0 (en) | 2025-05-21 |
| JP7664947B2 (ja) | 2025-04-18 |
| CO2022017072A2 (es) | 2022-12-09 |
| AU2021264528A1 (en) | 2023-01-19 |
| US20230081548A1 (en) | 2023-03-16 |
| TWI874645B (zh) | 2025-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3036330T3 (en) | Imidazopyridazines as modulators of il-17 | |
| CN102791693B (zh) | 丙型肝炎病毒抑制剂 | |
| JP7558334B2 (ja) | ＰＩ３Ｋ－γ阻害剤としてのアミノピラジンジオール化合物 | |
| JP5925394B2 (ja) | 抗レトロウイルス剤としての（ヘテロ）アリールアセトアミド誘導体 | |
| US10287286B2 (en) | Compounds | |
| TW201100401A (en) | Hepatitis C virus inhibitors | |
| TW200934486A (en) | Hepatitis C virus inhibitors | |
| ES2906258T3 (es) | 6-aminopiridin-3-ilo tiazoles como moduladores de ROR gamma t | |
| WO2017100668A1 (en) | Inhibitors of bruton's tyrosine kinase and methods of their use | |
| JP6334066B2 (ja) | ヤヌスキナーゼ阻害剤としての置換されたＮ−（ピロリジン−３−イル）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−アミン | |
| KR20250136325A (ko) | 염증성 질환 또는 바람직하지 않은 면역 반응과 연관된 질환을 치료 또는 예방하는 데 사용하기 위한 치환된 피리딘 | |
| BR112021001608A2 (pt) | derivado de amida heteroaromático inovador e medicamento contendo o mesmo | |
| WO2024233900A1 (en) | Gsk3a inhibitors and methods of use thereof | |
| WO2020187292A1 (zh) | 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用 | |
| CN120603813A (zh) | 2-氨基-n-(4-氨基-3,4-二氧代-1-(2-氧代吡咯烷-3-基)丁-2-基)苯甲酰胺衍生物作为蛋白酶抑制剂用于治疗或预防冠状病毒感染 | |
| ES2559295T3 (es) | Un compuesto para el tratamiento de la hepatitis C | |
| EA049631B1 (ru) | Имидазопиридазины в качестве модуляторов il-17 | |
| HK40067217A (zh) | Ep2拮抗剂 | |
| HK40044910A (en) | Modulators of the integrated stress pathway |